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Abstract
Serum Gc protein (known as vitamin D3–binding protein) is the precursor for the principal macrophage-activating
factor (MAF). The MAF precursor activity of serum Gc protein of prostate cancer patients was lost or reduced
because Gc protein was deglycosylated by serum α-N -acetylgalactosaminidase (Nagalase) secreted from cancer-
ous cells. Therefore, macrophages of prostate cancer patients having deglycosylated Gc protein cannot be acti-
vated, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized β-galactosidase
and sialidase generated the most potent MAF (termed GcMAF) ever discovered, which produces no adverse effect
in humans. Macrophages activated by GcMAF develop a considerable variation of receptors that recognize the
abnormality in malignant cell surface and are highly tumoricidal. Sixteen nonanemic prostate cancer patients re-
ceived weekly administration of 100 ng of GcMAF. As the MAF precursor activity increased, their serum Nagalase
activity decreased. Because serum Nagalase activity is proportional to tumor burden, the entire time course anal-
ysis for GcMAF therapy was monitored by measuring the serum Nagalase activity. After 14 to 25 weekly admin-
istrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of
healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.
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Introduction
Prostate cancer is the most common malignancy among elderly men.
Treatment of the metastatic cancer with hormone therapy tempo-
rarily controls symptoms in 70% to 80% of patients [1]. After a re-
mission period, a relapse invariably occurs. After progression, no
effective treatment is readily available, and the median survival is ap-
proximately 6 months in duration [2]. Therefore, progressive metas-
tatic hormone-refractory disease remains a therapeutic challenge. In
light of the mechanisms believed to be involved in the development
of recurrent disease, vigorous effort is being focused on the identifi-
cation of nonendocrine treatments [2–5]. However, therapeutic ap-
proaches capable of tumoricidal to hormone-refractory cancerous
cells and improving the quality of life are limited to a certain immu-
notherapy without causing adverse effects.
Intratumor administration of bacille Calmette–Guérin (BCG) or
other bacterial cells can result in regression of local and metastasized
tumors, suggesting the development of specific immunity against the
tumors [6,7]. However, administration of BCG into noncancerous
normal tissues results in no significant effect on the tumors. Inflamed
noncancerous normal tissues release membranous lipid metabolites, ly-
sophosphatidylcholine (lyso-Pc) and other lysophospholipids, which ef-
ficiently activate macrophages [8–10]. Inflamed cancerous tissues also
release lipid metabolites, lysoalkylphospholipids and alkylglycerols,
because cancerous cell membranes contain alkylphospholipids [11–
13]. Both lysoalkylphospholipids and alkylglycerols are approximately
400 times more potent macrophage-activating agents than lysophos-
pholipids in terms of the minimal dosages required for the optimal
macrophage activation [12–16]. This suggests that highly activated
macrophages can kill cancerous cells and also explains why intratumor
inflammation eradicates cancerous cells [14,15].
The inflammation-derived macrophage activation is the principal
macrophage activation process, which requires serum Gc protein
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(known as vitamin D3–binding protein) [17–19] and participation of
B and T lymphocytes [8–10,20–24]. Gc protein carries one trisaccha-
ride (Figure 1) consisting of N -acetylgalactosamine with dibranched
galactose and sialic acid termini at 420 threonine residue [20–24].
This oligosaccharide is hydrolyzed by the inducible membranous
β-galactosidase (Bgli) of inflammation-primed (or lyso-Pc–treated) B
lymphocytes to yield amacrophage-proactivating factor. This is further
hydrolyzed by the membranous Neu-1 sialidase of T lymphocytes to
yield MAF, the protein with N -acetylgalactosamine as the remaining
sugar [20–24] (Figure 1a). Thus, Gc protein is the precursor for the
principal MAF [20–24]. However, theMAF precursor activity of pros-
tate cancer patient Gc protein is lost or reduced, because their serum
Gc protein is deglycosylated by serum α-N -acetylgalactosaminidase
(Nagalase) secreted from cancerous cells [25,26] (Figure 1b). Degly-
cosylated Gc protein cannot be converted to MAF, resulting in no
macrophage activation. Macrophages are the major phagocytic and
antigen-presenting cells. Because macrophage activation for phagocy-
tosis and antigen presentation to B and T lymphocytes is the first in-
dispensable step in the development of both humoral and cellular
immunity, lack of macrophage activation leads to immunosuppression
[25–30]. Advanced cancer patients have high serum Nagalase activi-
ties, resulting in no macrophage activation and severe immunosup-
pression that explain why cancer patients die with overwhelming
infection (e.g., pneumonia) [25,26].
Stepwise treatment of purified Gc protein with immobilized β-
galactosidase and sialidase generates the most potent MAF (termed
GcMAF) [20–24] (Figure 1c), which produces no adverse effects in
humans [14,15,23,27]. Administration of 100 ng of GcMAF to hu-
mans results in the maximal activation of macrophages with 30-fold
increased ingestion index and 15-fold increased superoxide-generating
capacity [23] in 3.5 hours. GcMAF also has a potent mitogenic capac-
ity to act on themyeloid progenitor cells, resulting in a 40-fold increase
in systemic macrophage cell counts in 4 days [23,31]. Such highly ac-
tivated systemic macrophages are chemotactically recruited to in-
flamed lesions by 180-fold increase of the macrophage cell counts
[31]. Macrophages activated by GcMAF develop a considerable vari-
ation of receptors that recognize the abnormality in cancerous cell
surface and kill cancerous cells [14,15,32–34]. All malignant cells
have membrane abnormalities in their cell surface. A series of glyco-
lipid, glycoprotein, and mucin antigens have been identified and des-
ignated as tumor-associated antigens on the cell surface of a wide
variety of human tumor cells [35]. When human macrophages were
treated in vitro with 100 pg GcMAF/ml for 3 hours and a prostate
cancer cell line LNCaP was added with an effector/target ratio of
Figure 1. Schematic illustration of the formation of MAF (a), deglycosylation of Gc protein (b), and stepwise treatment of Gc protein with
immobilized β-galactosidase and sialidase to generate GcMAF (c).Asterisk (*) indicates inflammation-primed B cells: B cells can be treated
with an inflamed membranous lipid metabolite, e.g., lysophosphatidylcholine.
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1.5, approximately 51% and 82% of LNCaP cells were killed by 4 and
18 hours of incubation, respectively [14,15]. This in vitro tumoricidal
capacity of macrophages activated by GcMAF led us to investigate the
therapeutic efficacy of GcMAF for prostate cancer. GcMAF therapy as
a single remedy modality can eradicate metastatic breast and colorectal
cancers most effectively [34,36]. Although, in recent years, prostate-
specific antigen (PSA) has been used as a diagnostic and prognostic
index for prostate cancer [37,38], more precision of prognostic index
is desirable for therapeutic efficacy of GcMAF for prostate cancer pa-
tients. Because the serumNagalase activity of cancer patients is directly
proportional to tumor burden [25,26,32,33], serum Nagalase activity
has been effectively used as a diagnostic index for a variety of cancers
[14,15,25,26,32,33,39] and as a prognostic index for radiation ther-
apy [25], surgical resection of tumors [26], and GcMAF therapy for
preclinical and clinical mammary adenocarcinoma models [32–34]
and colorectal cancers [36].
Materials and Methods
Chemicals and Reagents
Phosphate-buffered saline (PBS) contained 1 mM sodium phos-
phate and 0.15 M NaCl. When peripheral blood monocytes adhere
to the vessel substratum, they behave like macrophages that show
increased synthesis of hydrolases. For manipulation in vitro and culti-
vation of peripheral blood mononuclear cells containing monocytes/
macrophages (macrophages for short) and lymphocytes (B and T
cells), 0.1% egg albumin–supplemented RPMI-1640 medium (EA
medium) was used. Sera for isolation of Gc1 protein (major Gc iso-
form) were donated by members of the institute and were routinely
screened to be virus-free using ELISA assays for antibodies against
human immunodeficiency and hepatitis B and C viruses (Cambridge
Biotechnology, Cambridge, UK, and Abbott Laboratories, Abbot
Park, IL). Gc protein was purified by vitamin D–affinity chromatog-
raphy [23,40]. β-Galactosidase and sialidase were purchased from
Boehringer Mannheim Biochemicals, Indianapolis, IN, and were im-
mobilized on Sepharose [21–23]. Lysophosphatidylcholine (lyso-Pc)
and p-nitrophenyl N -acetyl-α-D-galactosaminide were purchased
from Sigma Chemical Co. (St. Louis, MO).
Procedure for Preparation of GcMAF
Serum was heat-inactivated at 60°C for 1 hour and was mixed with
30% saturated ammonium sulfate that precipitates Gc protein frac-
tion [41]. The precipitate was dissolved in PBS (pH 7.4) containing
0.5% Triton X-100 and 0.3% tri-n-butyl phosphate and was kept
overnight at room temperature to resolve the lipid containing micro-
bial contaminants, including enveloped viruses, if any. The samples
were precipitated by 30% saturated ammonium sulfate, dissolved in
citrate buffer at pH 4.0, and kept overnight. Gc protein was purified
using 25-hydroxyvitamin D3–affinity chromatography [40]. This
chromatographic specificity to Gc protein yields highly pure Gc
protein and eliminates all possible contaminations of macromolecules.
Electrophoretic analysis proved the purity of Gc protein (MW52,000).
Stepwise incubation of the purified Gc protein with immobilized β-
galactosidase and sialidase yielded probably the most potent MAF
(GcMAF) ever discovered [21–23] (Figure 1c). The immobilized en-
zymes were removed by centrifugation. Thus, GcMAF is pure and free
from contamination of the enzymes. The final product, GcMAF, was
filtered through a low protein-binding filter, Millex-HV (Millipore
Corp., Bedford, MA) for sterilization.
Because the molecular structure of GcMAF is identical to that of
native human MAF (Figure 1, a and c), it should have no adverse
effects on humans. In fact, numerous administrations (more than
10 times for 3- to 6-month period) of GcMAF (100–500 ng/human)
to 12 humans showed no signs of adverse effects [15,23]. The optimal
human dose of GcMAF, to achieve phagocytic capacity by 30-fold in-
creased ingestion index and 15-fold increased superoxide-generating
capacity of peripheral blood monocytes/macrophages, was found to
be approximately 100 ng/human. Quality control of preparation of
GcMAF was performed for activity, sterility, and safety tests.
GcMAF Therapy for Prostate Cancer Patients
Participants. A group of 16 nonanemic prostate cancer patients
was included in this study. Although serum Nagalase activities of
prostatectomized patients indicate significant amounts of metasta-
sized tumor cells, computed tomography did not detect metastasized
tumor lesions in other organs. These patients received GcMAF ther-
apy exclusively and excluding combination therapy with erythro-
poiesis induction. Thus, anemic prostate cancer patients were not
eligible in the program. The study was approved by the institutional
research and ethic committees of Nagasaki Immunotherapy Group,
Nagasaki, Japan, and by the institutional review board of Hyogo Im-
munotherapy Group, Hyogo, Japan. The participants gave written
informed consent before entering the study.
GcMAF administration. Because the half-life of the activated
macrophages is approximately 6 days [12,13], 100 ng of GcMAF
was administered intramuscularly once a week.
Procedures to be used for clinical study and study parameters. Serum
samples (>2 ml) were weekly or biweekly collected immediately before
each GcMAF administration and were used for prognostic analysis.
Detailed assessment of patient response to each GcMAF adminis-
tration was performed by determining both MAF precursor activity
of serum Gc protein and serum Nagalase activity. Because serum
Nagalase activity is proportional to tumor burden [26,32,33], kinetic
assessment of curative response to GcMAF therapy was performed by
determining serum Nagalase activity as a prognostic index during the
entire therapeutic course of all 16 patients. The PSA values were also
determined immediately before this study.
Assay for MAF Precursor Activity of Patient Serum Gc Protein
Blood samples of healthy humans were collected in tubes contain-
ing EDTA to prevent coagulation. A 5-ml blood sample and 5 ml of
saline (0.9% NaCl) were mixed and gently laid on a 15-ml centrifuge
tube containing 3 ml of Lymphoprep (similar to Ficoll; Polysciences,
Inc, Warrington, PA) and centrifuged at 800g for 15 minutes. The
dense white cell band as peripheral blood mononuclear cells contain-
ing monocytes/macrophages (macrophages for short) and lympho-
cytes (B and T cells) was collected using a Pasteur pipette. The
white cell mixture was washed twice with PBS, suspended in EA me-
dium, and placed in 16-mm wells. Incubation for 45 minutes in a
5% CO2 incubator at 37°C allowed adherence of macrophages to the
plastic surface. The mixture of lymphocytes and adherent macro-
phages of healthy humans was treated with 1 μg lyso-Pc/ml in EA
medium for 30 minutes. Because of the adherence of macrophages to
the plastic substrata, lymphocytes and macrophages were separately
washed with PBS, admixed, and cultured in EA medium containing
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0.1% serum of prostate cancer patients or healthy human as a source of
Gc protein. After 3 hours of cultivation, the macrophages were assayed
for superoxide-generating capacity [25,26]. The macrophages were
washed with PBS and incubated in 1 ml of PBS containing 20 μg
of cytochrome c for 10 minutes. Thirty minutes after the addition
of phorbol-12-myristate acetate (5 μg/ml), the superoxide-generating
capacity of themacrophages was determined spectrophotometrically at
550 nm. The data were expressed as nanomoles of superoxide pro-
duced per minute per 106 cells (macrophages). These values represent
the MAF precursor activity of patient serum Gc protein [28,29]. Lost
or reduced MAF precursor activity of patient serum Gc protein is ex-
pressed as a decrease in superoxide generation compared with the
healthy human Gc protein control. Thus, the MAF precursor activity
measures both the ability of each patient to activate macrophages and
the immune potential. However, loss of MAF precursor activity results
in immunosuppression.
Cultivation of the mixture of lyso-Pc–treated lymphocytes and
macrophages in EA medium without serum results in the production
of 0.5 to 0.85 nmol superoxide/min per 106 cells [41,42]. Thus, if
patient serum (0.1%) generates <0.85 nmol superoxide/min per 106 cells,
the precursor activity of patient serum Gc is considered to be lost.
Determination of Nagalase Activity in Patient Blood Stream
Patient sera (300 μl) were precipitated with 70% saturated ammo-
nium sulfate. The precipitates were dissolved in 50 mM sodium cit-
rate buffer (pH 6.0) and were dialyzed against the same buffer at 4°C
for 2 hours. The dialysates were made up to 1 ml in volume and
assayed for Nagalase activity [25,26]. Substrate solution (250 μl)
contained 5 μmol of p-nitrophenyl N -acetyl-α-D-galactosaminide
in 50 mM citrate buffer (pH 6.0). The reaction was initiated by
the addition of 250 μl of the dialyzed samples, kept at 37°C for
60 minutes, and terminated by adding 200 μl of 10% TCA. After
centrifuging the reaction mixture, 300 μl of 0.5 M Na2CO3 solution
was added to the supernatant. The amount of released p-nitrophenol
was determined spectrophotometrically at 420 nm and was expressed
as nanomoles per minute per milligram protein [25,26]. Protein con-
centrations were estimated by the Bradford method [43].
The half-life of Nagalase activity in vivo is less than 24 hours, be-
cause we observed a sudden drop of Nagalase activity in 24 hours
after resection of the tumor [26]. However, Nagalase activity in the
collected serum is extremely stable, probably because of the presence
of a product inhibitor, and is highly reproducible after storage of sera
at 4°C for more than 6 months [26].
Healthy control sera exhibit low levels (0.35–0.65 nmol/min per
milligram) of the enzyme activity. This is the enzyme activity of α-
galactosidase that can catabolize the chromogenic substrate (i.e., p-
nitrophenyl N -acetyl-α-D-galactosaminide) for Nagalase [25,26,28].
The reduction in serum Nagalase activity to 0.65 nmol/min per mil-
ligram or less in patients during GcMAF therapy serves as demonstra-
tion that tumor burden has been eradicated.
Results
Therapeutic History and Immunodiagnostic Parameters of
Nonanemic Prostate Cancer Patients
The therapeutic history of 16 prostate cancer patients before
GcMAF therapy is summarized in Table 1. Nine patients received
prostatectomy with or without hormone therapy. A total of 12 pa-
tients received hormone therapy. Because the fate and staging of the
malignant disease correlate with tumor burden and the degree of im-
munosuppression [25,26], the immune potency and tumor burden
index for each patient must be determined before entering GcMAF
therapy regardless of the lapse of time after prostatectomy and/or
hormone therapy (Table 1).
Because macrophage activation for phagocytosis and antigen pre-
sentation to B and T cells is the first indispensable step for immune
development, the lack of macrophage activation leads to immunosup-
pression [26,27]. Because serum Gc protein is the precursor of the
principal MAF, the MAF precursor activity of patient serum Gc pro-
tein was first to be determined. As shown in Table 1, the MAF precur-
sor activities of serum Gc protein of prostate cancer patients were lost
(<0.85 nmol superoxide/min per 106 cells) or reduced. Because loss or
decrease in the MAF precursor activity of patient Gc protein results
from deglycosylation of the Gc protein by serum Nagalase secreted
from cancerous cells [25,26] (Figure 1b), serum Nagalase activities
of these cancer patients were determined. Patients having lower precur-
sor activity of the Gc protein carried higher serum Nagalase activity
(Table 1). Because serumNagalase activity of cancer patients is directly
proportional to their tumor burden [26,32,33], the serum Nagalase
activity indicates the total amount of the primary tumor (if not pros-
tatectomized) and the metastasized tumor cells. Thus, the serum
Nagalase activity of individual patients should be used as a baseline
control for prognostic analysis during GcMAF therapy. The PSA
values of each patient at the initial diagnosis, after prostatectomy,
and before entering GcMAF therapy are also shown in Table 1.
The MAF Precursor Activity of Gc Protein and Serum
Nagalase Activity as Prognostic Parameters during GcMAF
Therapy for Prostate Cancer Patients
In the course of GcMAF therapy,MAF precursor activity and serum
Nagalase activity of five patients were analyzed. As GcMAF therapy
progressed the MAF precursor activity of all five patients increased
and their serum Nagalase activity decreased inversely as shown in
Table 2. To illustrate quantitative correlation of these parameters,
Table 1. Therapeutic History and Diagnostic Parameters of Prostate Cancer Patients.
Patient Therapeutic History Pre–GcMAF Therapy*
No. Age (years) PSA Surgery PSA Endocrine PSA Precursor Nagalase
1 64 16.5 No — Yes 21.7 0.82 4.92
2 76 2.5 Pxy <0.1 None 3.52 3.19 2.30
3 46 35.4 Pxy 0.3 Yes 8.2 2.44 2.85
4 68 4.5 No — Yes 4.2 2.26 3.25
5 68 68.4 Pxy 0.2 Yes 0.09 3.77 3.15
6 50 20.5 Pxy 0.1 Yes 1.0 2.20 3.73
7 56 18.0 Pxy 0.2 Yes 3.4 2.88 1.95
8 61 25.3 Pxy 0.2 None 5.8 2.29 3.45
9 56 8.4 No — Yes 6.5 2.85 2.50
10 53 8.0 Pxy 0.1 None 3.8 0.85 4.72
11 66 16.6 No — Yes 10.2 2.05 4.02
12 66 22.5 Pxy 0.1 Yes 4.2 2.75 3.62
13 68 6.2 No — Yes 10.1 1.02 5.34
14 73 3.1 No — Yes 3.2 2.23 3.52
15 58 6.0 Pxy 0.1 None 7.8 1.68 4.32
16 63 6.6 No — Yes 5.8 2.22 3.58
C† 4.84 0.39‡
Pxy indicates prostatectomy.
*Pre–GcMAF therapy assays for PSA, precursor activity (nmol/min per 106 cells), and Nagalase
(nmol/min per milligram). The precursor activity of <0.9 nmol/min per 106 cells is unable to
develop phagocytic capacity of macrophages and is considered to be loss of the precursor activity.
†Average of seven healthy controls.
‡This activity level is the enzyme activity of α-galactosidase and not of Nagalase.
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the time course ofMAF precursor activity of individual prostate cancer
patient was plotted against their corresponding serum Nagalase activ-
ity. As GcMAF therapy progressed, the MAF precursor activity in-
creased with a concomitant decrease in serum Nagalase activity as
shown in Figure 2. These prognostic parameters of all five individual
patients fall in the same linear inverse correlation. When theMAF pre-
cursor activity increased toward the healthy control value, serum Na-
galase activities of these patients decreased toward the healthy control
level (Figure 2). Thus, these malignancy parameters of prostate cancer
patients served as excellent prognostic indices. Because the serum Na-
galase is proportional to tumor burden [26,32,33], as GcMAF therapy
progressed, serum Nagalase activity decreased and, concomitantly, tu-
mor burden decreased. Thus, the entire time course analysis of tumor
burden during GcMAF therapy of all 16 patients should be performed
bymeasuring serumNagalase activity as a prognostic index. The kinetic
decrease of serum Nagalase activity allows us to envision a curative pro-
cess of the malignancy as a decrease of tumor burden.
Time Course Study of Serum Nagalase Activity of Prostate
Cancer Patients during GcMAF Therapy
Time course analyses of serum Nagalase activity of the prostate
cancer patients assess the efficacy of GcMAF. These patients had
the initial Nagalase activities ranging from 1.95 to 5.34 nmol/min
per milligram (Table 1). As shown in Figure 3, the serum Nagalase
activities of all 16 patients decreased as GcMAF therapy progressed.
After approximately 14 to 25 administrations (14–25 weeks) of
100 ng of GcMAF, all 16 patients had very low serum Nagalase activ-
ity levels equivalent to those of healthy control values ranging from
0.37 to 0.68 nmol/min per milligram. These low enzyme activities
are those of α-galactosidase and not of malignant-specific Nagalase
[25,26]. Because serum Nagalase activity is proportional to tumor
burden, the results suggest that these patients are free of cancerous
cells. During 7 years of observation after completion of GcMAF ther-
apy, these patients showed no increase in their serum Nagalase activ-
ities, indicating no recurrence of prostate cancer. Furthermore,
annual computed tomographic scans of these patients confirmed
them being tumor recurrence–free for the 7 years.
Curative Rate of GcMAF Therapy for Prostate Cancer
Depends on the Degree of Cell Surface Abnormality
Poorly differentiated (termed undifferentiated) cancer cells should
have more abnormality in cell surface than moderately/immediate
differentiated (termed differentiated for short) cancer cells [34,36].
Because the activated macrophages efficiently recognize and rapidly
kill cancer cells having more abnormality, the activated macrophages
kill undifferentiated cells more rapidly than differentiated cells
[34,36]. Thus, the rapidly decreasing serum Nagalase activities during
GcMAF therapy imply more abnormality in undifferentiated cells. As
shown in the time course study of GcMAF therapy in Figure 3, the
serum Nagalase activity of patient nos. 2, 5, 7, 8, 9, 11, 12, and 16,
for example, decreased sharply in the first few weeks (up to 4 weeks),
followed by a slow decrease during the remaining therapeutic period
(approximately 8–14 weeks). These biphasic tumor regression graphs
suggest that undifferentiated cells are mixed with differentiated cells
Table 2. Correlation of the MAF Precursor Activity of Individual Prostate Cancer Patients with
Their Serum Nagalase Activity during GcMAF Therapy.
Patient No. Time Assayed (weeks) Precursor Activity
Superoxide (nmol)
Nagalase
(nmol/min per milligram)
1 (7)* 0 2.88 1.95
1 3.38 1.74
2 3.51 1.59
4 3.61 1.32
6 3.44 1.19
10 3.92 1.08
12 4.05 0.96
21 4.13 0.68
2 (8) 0 2.29 3.45
1 2.40 2.89
2 2.62 2.75
3 2.88 2.43
4 2.92 2.21
6 3.21 2.02
10 3.33 1.69
14 3.62 1.38
17 3.72 0.94
21 4.29 0.66
3 (6) 0 2.20 3.73
1 2.28 3.09
2 2.75 2.73
4 3.18 3.34
8 3.03 2.18
11 3.33 2.01
15 3.50 1.89
19 3.65 1.67
23 3.75 1.29
26 4.24 0.67
4 (12) 0 2.75 2.62
1 3.11 3.16
2 3.16 2.01
3 3.20 1.82
9 3.25 1.71
16 3.35 1.43
22 4.23 0.64
5 (13) 0 1.02 5.34
1 1.22 5.11
2 1.37 4.87
3 1.68 4.31
4 1.97 4.12
9 2.22 3.54
14 3.81 1.10
18 3.79 0.83
24 4.28 0.72
Control† 4.25 0.52
*The numbers in parentheses refer to the patient nos. in Table 1.
†The mean value of five healthy controls.
Figure 2. Inverse correlation between the MAF precursor activity
of serum Gc protein and serum α-N -acetylgalactosaminidase (Na-
galase) activity of prostate cancer patients during GcMAF therapy.
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within the tumors [34,36]. Thus, undifferentiated cells were killed rap-
idly during the first few weeks, and the differentiated cells were killed
slowly in the remaining GcMAF therapeutic period. These mixed-cell
populations seemed to be developed by differentiation during the
growth of undifferentiated tumor cells [34,36]. In contrast, patient
nos. 1, 6, 10, 13, and 15 showed that their serum Nagalase activity
decreased linearly and rapidly reached control values between 14
and 18 weeks. These linear, declining curative rates are slower than
the curative rates of the undifferentiated population of the previously
mentioned mixed population (i.e., undifferentiated and differentiated)
of prostate cancers. Therefore, the latter group of tumors is already
differentiated and further differentiation of these tumors did not occur
during tumor growth. Similar results were also observed during
GcMAF therapy for metastatic breast cancer patients [34].
Correlation between Serum Nagalase Activity and PSA Levels
during GcMAF Therapy
Because serum Nagalase activity is an excellent index for the esti-
mation of tumor burden [26,32], serum PSA levels were compared
with serum Nagalase activity during GcMAF therapy of five prostate
cancer patients. As shown in Table 3, PSA levels of prostatectomized
patients decreased as serum Nagalase decreased during GcMAF ther-
apy. In patients without tumor resection, however, although serum
Nagalase activity decreased as GcMAF therapy progressed, their
PSA values remained unchanged. The result suggests that the PSA
derived from tumor-bearing prostate did not change while tumor
burden decreased. Because tumor-induced inflammation in the non-
cancerous prostate tissues causes secretion of PSA [38], the PSA pro-
duced from these inflamed noncancerous prostate tissues cannot be
changed by the decrease in tumor burden.
Discussion
Prostatic cancer diagnosis and prognosis have been aided by the
availability of PSA measurement [37,38]. When patients received
radical prostatectomy, a sudden drop of high PSA levels to very
low values was observed (Table 1). Thus, PSA is predominantly pro-
duced from primary tumor lesions in prostate compared with the
metastasized lesions. Although serum Nagalase decreased during
GcMAF therapy of patients with tumor-bearing prostate, PSA re-
mained unchanged (Table 3). Therefore, PSA values cannot be used
for prognostic assays during GcMAF therapy.
Prostate-specific antigen, as a serine protease, has been considered
to be specific to prostatic malignancy and one of extracellular matrix–
degrading enzymes that is required for invasiveness of cancerous tis-
sues [44,45]. However, normal prostatic inflamed tissue can release
PSA [38], particularly in certain disease states such as benign prostate
hypertrophy and prostatitis. The invasive enzymatic action of the
cancerous PSA onto surrounding noncancerous prostatic tissues in-
duces a mild inflammatory process that can cause noncancerous pros-
tate cells to release PSA. Because of the predominance of PSA
production in prostatic tissues, PSA assay cannot accurately estimate
the fractional loss of tumor burden. This is confirmed in the present
Figure 3. Time course study of GcMAF therapy of 16 prostate can-
cer patients with serum α-N -acetylgalactosaminidase (Nagalase)
as a prognostic index.
Table 3. Correlation between Serum Nagalase Activity and PSA during Time Course Study of
GcMAF Therapy for Prostate Cancer Patients.
Patient No. Age (years) Assayed Weeks
After first GcMAF
Nagalase Specific Activity
(nmol/min per milligram)
PSA (ng/ml)
A1 67 0 2.53 27.60
2 2.27 27.20
4 2.00 25.90
5 1.94 28.25
6 1.93 23.79
12 1.47 26.74
24 0.69 25.95
A2 83 0 3.66 18.02
2 2.94 15.64
3 2.74 13.91
4 2.63 18.77
5 2.55 21.94
10 0.72 18.53
A3 60 0 2.18 58.49
3 1.85 42.49
4 1.77 56.54
5 1.62 63.61
6 1.62 82.30
7 1.54 65.20
10 0.84 58.45
A4 (prostatectomy) 76 0 3.94 11.85
1 3.44 10.56
4 2.46 5.22
12 1.92 0.33
15 1.36 0.24
20 0.69 0.10
A5 (prostatectomy) 66 0 2.00 5.82
1 1.79 5.43
2 1.69 4.05
4 1.49 3.12
6 1.38 2.77
9 1.21 2.46
13 1.19 1.89
18 1.07 0.86
21 0.92 0.14
26 0.62 0.10
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article by comparative analysis of serum Nagalase activity with PSA
during GcMAF therapy (Table 3).
Furthermore, PSA, being a serine protease, may not be restricted to
the prostate. Prostate-specific antigen has been shown to be produced
by extraprostatic tissues, including salivary gland neoplasm, cloaco-
genic glandular epithelium, and normal and cancerous female breast
tissues [46–48]. Thus, PSA is less specific to prostatic malignancy.
In contrast, Nagalase is secreted exclusively from cancerous cells
but not from normal tissues (even inflamed noncancerous tissues).
Thus, the level of Nagalase activity in blood stream is proportional
to the tumor burden in the hosts [25,28,29] and has been used as a
prognostic index for GcMAF therapy for preclinical and clinical can-
cer models [14,15,25,32–34,36]. Serum Nagalase deglycosylates se-
rum Gc protein. Deglycosylated Gc protein loses its MAF precursor
activity and cannot be converted to MAF, resulting in no macrophage
activation leading to immunosuppression [25,26]. Thus, measure-
ment of serum Nagalase activity and the MAF precursor activity of
serum Gc protein allows us to envision the degree of immunosup-
pression and the state of the disease.
Because the trisaccharide of Gc protein in the blood stream is effi-
ciently deglycosylated by serum Nagalase [25–28] (Figure 1b), the se-
rum Nagalase seems to be an endo-Nagalase but not as an exo-enzyme
under colloidal serum environment. When GcMAF (100 ng) is ad-
ministered to cancer patients, GcMAF is not affected by the patient’s
serum Nagalase [34,36], bypasses the deglycosylated Gc protein, and
directly acts on macrophages for an extensive activation. Such highly
activated macrophages develop a considerable variation of receptors,
recognize the abnormality of malignant cell surface, and eradicate can-
cerous cells [34,36]. This fundamental nature of macrophages to rec-
ognize abnormality of malignant cells is universal to all types of
cancers. In fact, administration of GcMAF (100 ng/week) to nonane-
mic cancer patients showed curative effects on a variety of cancers in-
discriminately [15,33,34,36]. The types of cancer so far tested are
prostate, breast, colon, stomach, liver, lung (including mesothelioma),
kidney, bladder, uterus, ovary, head/neck, melanoma, and fibrosarcoma
[34]. Progress of GcMAF therapy for these cancers is monitored by
the measurement of the malignant cell–specific serum Nagalase activ-
ity that is universally found in patients with a wide variety of cancers
[25,26]. Curative rates of various cancers depend on the degree of
cell surface abnormality that corresponds to the grade of differentia-
tion of the malignant cells. Precision of measurement of Nagalase ac-
tivity allowed us to determine the degree of cell surface abnormality
by the curative rate during GcMAF therapy. Undifferentiated tu-
mor cells are killed more efficiently than differentiated cells [34,36].
In fact, adenocarcinomas such as breast and prostate cancer cells are
undifferentiated and killed rapidly by the activated macrophages,
whereas well-differentiated cancer cells such as squamous carcinoma
cells are slowly killed by the activated macrophages. Faster curative
rates, requiring less than 22 weeks, were always observed during
GcMAF therapy for breast cancer [34]. In contrast, GcMAF therapy
for well-differentiated squamous cell carcinomas such as head/neck
cancers requires more than 75 weeks. Thus, the faster curative rate
of prostate cancer is due to the efficient macrophage recognition of
the abnormality of the prostate cancer cell surface. However, a variety
of cancers contain the mixed population of undifferentiated and dif-
ferentiated cells within a tumor (e.g., breast and colorectal cancers)
[34,36]. This type of fine differentiation in prostate cancer has been
known for many years. In 1977, Gleason [49] separated histologic
patterns of prostate cancer into a grading 1 to 5 patterns of decreas-
ing differentiation, tumor pattern grade 1 being most differentiated
and pattern grade 5 being least differentiated (poorly differentiated or
undifferentiated). Tumor pattern grade 3 (Gleason grade 3) is the
most common histologic pattern and is considered moderately well
differentiated. However, one can readily interpret the histologic pat-
tern of the grade 3 (schematic diagram developed by Gleason) as a
mixture of differentiated cells (grade 1) and least differentiated (un-
differentiated) cells (grade 5). This can explain the biphasic tumor
regression graphs during GcMAF therapy for most prostate cancer
being a mixture of differentiated and undifferentiated cells.
Because of the availability of precision measurement of serum Na-
galase, the curative rate measurements of tumors during GcMAF ther-
apy and the estimation of the degree of tumor differentiation have
been possible. Therefore, the significance of GcMAF therapy for can-
cers has been greatly enhanced by the discovery of cancer cell–specific
Nagalase that can accurately monitor the rate of tumor regression dur-
ing GcMAF therapy [32–34,36].
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